Abstracts tagged "Disease Activity"

Abstract Number: 1471 • 2016 ACR/ARHP Annual Meeting
Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment
Isabelle Amigues¹, Jon T. Giles², Afshin Zartoshti³, Rachelle Morgenstern⁴, Raul Flores⁵, Sabahat Bokhari⁶ and Joan Bathon⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁴Cardiology, columbia university college of physicians and surgeons, New York city, NY, ⁵Medicine, Columbia University, New York Presbyterian, New York city, NY, ⁶Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Symptomatic heart failure (HF) and HF-associated mortality rates are higher in RA compared with the non-RA population, even after controlling for coronary artery…
Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Agnes Szentpetery¹, Natsumi Ikumi¹, Brian Kirby² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
Abstract Number: 2082 • 2016 ACR/ARHP Annual Meeting
Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Jianlin Huang¹, Hongzhi Wang², Jing Yang³, Wenqiang Fan⁴, Hua Wei⁵, Rong Mu⁶, Xinwang Duan⁷, Xiangyuan Liu⁸, Fang He⁹, Zhenchun Zhang¹⁰, Fei Xiao¹¹, Hui Xiao¹¹, Yuhua Jia¹¹, Yuan Liu¹¹, Li Zhang¹¹, Bing Wu¹¹ and Xiaofeng Li¹², ¹Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁸Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ⁹Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁰People's Hospital of Linyi, Shandong, Linyi, China, ¹¹Gothic Internet Technology Corporation, Shanghai, China, ¹²The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-target (T2T) is a widely accepted cretria as…
Abstract Number: 2518 • 2016 ACR/ARHP Annual Meeting
Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
Nicola J Gullick¹, Fowzia Ibrahim², Aneela Mian¹, Alexandra Vincent³, Gabriel Panayi¹, Brian Tom⁴, David L. Scott¹ and Bruce Kirkham³, ¹Rheumatology, King's College London, London, United Kingdom, ²Academic Rheumatology Dept, King's College London, London, United Kingdom, ³Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
Background/Purpose: There has been increasing emphasis on intensive treatment of RA but little direct evidence of the impact of such strategies on long term outcome.…
Abstract Number: 2780 • 2016 ACR/ARHP Annual Meeting
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…
Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting
Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Susan J. Bartlett^1,2, Orit Schieir³, Kathleen Andersen⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet E. Pope⁹, J Carter Thorne¹⁰, Diane Tin¹¹, Vivian P. Bykerk¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁶1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
Abstract Number: 31 • 2016 ACR/ARHP Annual Meeting
Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)
Charlotte Jacquemin¹, Herve Servy², Anna Molto³, Jeremie Sellam⁴, Violaine Foltz¹, Frédérique Gandjbakhch¹, Christophe Hudry³, Stéphane Mitrovic¹, Bruno Fautrel¹ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Sanoia, La Ciotat, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology, Saint-Antoine Hospital, Paris, France
Background/Purpose: The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a…
Abstract Number: 517 • 2016 ACR/ARHP Annual Meeting
Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis
BEATRIZ RODRIGUEZ-LOZANO¹, Jorge Luis Garnier Rodríguez², Jerián González Febles³, Shashi Dadlani⁴, Ivan Ferraz-Amaro¹, Esmeralda Delgado Frías¹, Federico Díaz-González¹ and Mariano Sanz Alonso³, ¹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ²Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ³Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ⁴Periodontology, Dental Clinic Garnier, S/C Tenerife, Spain
Background/Purpose: Recent clinical data show a clear association between periodontitis (P) and RA. However, there is controversy over whether severity of P is associated with…
Abstract Number: 757 • 2016 ACR/ARHP Annual Meeting
Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)
Richard A. Furie¹, Margaret Mitrane², Enxu Zhao³ and Patrice Becker⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Manhattan BioPharm Consultants, New York, NY, ³Research and Development; Biometrics, Mallinckrodt Pharmaceuticals, Ellicott City, MD, ⁴Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Multiple outcome measures have been utilized in SLE clinical trials. Consistency of response assessed by different instruments enhances confidence in the efficacy of pharmacologic…
Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting
Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative
L Rosenblatt¹, K Price¹, Y Doleh¹, A Szymialis¹, M Eaddy², A Ogbonnaya², H-C Shih² and L Lamerato³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Xcenda, LLC, Palm Harbor, FL, ³Henry Ford Health System, Detroit, MI
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
Abstract Number: 1484 • 2016 ACR/ARHP Annual Meeting
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Saurash Reddy, Xiaobo Meng and Carol Hitchon, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) has been established as a risk factor for cardiovascular disease (CVD), with systemic inflammation being linked with atherosclerosis. Traditional CVD risk…
Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Christopher T. Ritchlin⁴, Doquyen H. Huynh³, Renganayaki Pandurengan², Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
Abstract Number: 2152 • 2016 ACR/ARHP Annual Meeting
S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation
Lucie Andres Cerezo¹, Barbora Šumová¹, Klára Prajzlerová¹, David Veigl², Karel Pavelka¹, Jiří Vencovský³ and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Calgizzarin (S100A11) is a member of the S100 protein family that acts in different tumors via regulating number of biologic functions. Recent data suggest…
Abstract Number: 2539 • 2016 ACR/ARHP Annual Meeting
Analysis of Joints Susceptible to Rheumatoid Arthritis (RA) and Their Recovery Sequence Based on DAS28 and Physical Function Based on HAQ with Smart System of Disease Management (SSDM) in China：a Prospective Cohort Study
Rong Mu¹, Jing Yang², Hongzhi Wang³, Xinwang Duan⁴, Jianling Dong², Fengxiao Zhang⁵, Wenqiang Fan⁶, Huifang Guo⁷, Tong Xie⁸, Fei Xiao⁹, Hui Xiao⁹, Yuhua Jia⁹, Minjun Wang⁹, Yuan Liu⁹, Bing Wu⁹ and Zhanguo Li¹⁰, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³The First Hospital of Jiaxing, Jiaxing, China, ⁴Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Department of rheumatology, Hebei General Hospital, Shijiazhuang, China, ⁶Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁷The Second Hospital of Hebei Medical University, Shijiazhuang, China, ⁸Affiliated hospital of Guangdong medical University, Zhanjiang, China, ⁹Gothic Internet Technology Corporation, Shanghai, China, ¹⁰Peking University People's Hospital, Beijing, China
Background/Purpose: The disease activity score in 28 joints (DAS28) and health assessment questionnaire (HAQ) serve as guides for the treatment of rheumatoid arthritis (RA). Smart…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].